欧洲骨髓移植登记组回顾分析:HLA相合与替代供者异基因造血干细胞移植的结局演变
结果显示各供者组3年总生存率在近十年均提高,单倍体和脐血移植进步显著;除高危疾病外,相合同胞供者仍最优。
要点
- 各供者组3年总生存率在2006-10至2011-15期间均提高,单倍体和脐血移植进步最明显。
- 总生存改善主要由非复发死亡下降驱动,脐血移植者复发率较低。
- 除高危疾病外,相合同胞供者总生存仍优于其他供者;高危疾病中相合无关供者与之无差异。
核心结论
- 异基因造血干细胞移植总生存持续改善,单倍体和脐血移植进步显著,但传统供者 hierarchy 仍成立。
主要发现
- 总生存改善似乎由非复发死亡下降驱动,但脐血移植者复发率较低。
- 按新型三级疾病风险分层,相合同胞移植总生存仍优于其他供者,但高危疾病中相合无关移植总生存无差异。
临床怎么用
- 供者选择仍应优先考虑相合同胞,其次相合无关,再考虑其他供者;高危疾病可考虑相合无关供者。
- 单倍体和脐血移植的进步支持其作为替代供者的应用。
局限性
- 回顾性登记研究,存在缺失数据,采用链式方程多重插补处理。
- 未报告其他具体局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The introduction of donors other than HLA-matched siblings has been a pivotal change in stem cell transplantation. We aimed to assess the evolution of outcomes within donor groups over time and explore whether donor-recipient HLA disparity might be advantageous in patients with aggressive disease. METHODS: In this retrospective, multicentre study, we assessed the outcomes for adult patients (≥18 years) with haematological malignancies who underwent their first allogeneic hematopoietic stem cell transplantation (HSCT) between Jan 3, 2001, and Dec 31, 2015, and were reported to the European Society for Blood and Marrow Transplantation. The donor types studied were matched sibling, matched unrelated, mismatched unrelated, haploidentical, and cord blood donors. Unrelated non-cord-blood donors and recipients were typed at the allelic level for HLA-A, HLA-B, HLA-C, and HLA-DRB1. We evaluated trends in overall survival, non-relapse mortality, relapse incidence, progression-free survival, acute and chronic graft-versus-host disease (GVHD), and GVHD-free and relapse-free survival following transplantation from various donor types (matched sibling, matched unrelated, mismatched unrelated, haploidentical, and umbilical cord blood), and compared transplantation outcomes across three epochs (epoch 1: 2001-05; epoch 2: 2006-10; and epoch 3: 2011-15). We used Kaplan-Meier estimators for survival probabilities and cumulative incidence functions accounting for competing risks for probabilities of GHVD, relapse, and non-relapse mortality, using multiple imputations by chained equations to deal with missing data. In epoch 3, we directly compared outcomes by donor group, stratified by a novel three-level disease-risk scheme. FINDINGS: We included 106 188 patients in our analysis. The median follow-up was 4·1 years (IQR 1·7-7·7). Overall survival at 3 years increased with all donor groups between epochs 2 and 3 (matched sibling: 54·0% [95% CI 53·1-54·8] to 54·6% [53·6-55·6]; matched unrelated: 49·1% [48·0-50·2] to 51·6% [50·7-52·6]; mismatched unrelated: 37·4% [35·7-39·2] to 41·3% [39·5-43·1]; haploidentical: 34·5% [31·4-37·9] to 44·2% [42·1-46·3]; and cord blood 36·3% [33·9-39] to 43·7% [40·8-46·8]). Improvement in overall survival seems to be driven by a reduction in non-relapse mortality, except in cord blood HSCT recipients, who had a lower relapse incidence. Comparing donor groups across disease-risk strata using the novel disease-risk scheme, overall survival among recipients of matched sibling transplantations remained better than other donor groups except in high-risk disease, where overall survival with matched unrelated transplantations was not different. INTERPRETATION: Overall survival following allogeneic stem cell transplantation is improving with substantial progress among recipients of haploidentical and cord blood HSCT. Nonetheless, the traditional donor hierarchy of matched sibling donors followed by matched unrelated donors and then other donors holds. Our findings warrant further investigation and could inform decision making and the development of donor-selection algorithms. FUNDING: The Varda and Boaz Dotan Research Center in Haemato-Oncology, Tel Aviv University, and the Shalvi Foundation for Research.
引用
- Shouval R, Fein JA, Labopin M, et al. Outcomes of allogeneic haematopoietic stem cell transplantation from HLA-matched and alternative donors: a European Society for Blood and Marrow Transplantation registry retrospective analysis. Lancet Haematol. 2019. PMID: 31477550. doi:10.1016/S2352-3026(19)30158-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。